A5101888497- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Breast Lesions and Carcinomas
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Lung Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Immunotherapy and Immune Responses
- Estrogen and related hormone effects
- Multiple and Secondary Primary Cancers
- Vitamin D Research Studies
- Chronic Myeloid Leukemia Treatments
- Glioma Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- MRI in cancer diagnosis
- Helicobacter pylori-related gastroenterology studies
Hospital Universitari Arnau de Vilanova
2019-2025
Biomedical Research Institute of Lleida
2025
Hospital Arnau de Vilanova
2018-2024
Clinica Universidad de Navarra
2004-2024
Taunton & Somerset NHS Foundation Trust
2024
Somerset NHS Foundation Trust
2024
Hospital Universitari Joan XXIII de Tarragona
2024
Bellvitge University Hospital
2023
Universidad de Navarra
2004-2009
Background Gastric adenocarcinoma (GAC) imposes a considerable global health burden. Molecular profiling of GAC from the tumor microenvironment perspective through multi-omics approach is eagerly awaited in order to allow more precise application novel therapies near future. Methods To better understand tumor-immune interface GAC, we identified an internal cohort 82 patients that allowed integrative molecular analysis including mutational by whole-exome sequencing, RNA gene expression 770...
Neoadjuvant chemotherapy (NAC) is an optimal option in early breast cancer, but ER-positive/HER2-negative (luminal) still controversial, although a survival benefit has recently been observed when histological response by Symmans' method type 0 or I achieved. The 21-gene Oncotype DX Breast Recurrence Score® assay (Oncotype DX®) validated test to assess the of adjuvant these patients its role neoadjuvant setting less established. We analyzed results DX® cohort 122 consecutive selected receive...
Background: Radioembolization (RE) has potential benefits in local tumor control, liver hypertrophy, and as a strategy for transplant (LT) candidates. Methods: This study focuses on patients diagnosed with HCC ICC who underwent RE followed by either resection (LR) or LT between 2005–2020. These were initially not considered surgical candidates based oncological safety criteria, determined multidisciplinary team assessment. Clinicopathological data, postoperative outcomes, survival details...
Abstract Background The iliac crest free graft with internal oblique muscle (IOM) is used for the reconstruction of composite head and neck defects. This can cause a muscular defect in abdominal wall that requires complex reconstruction. We present case 43-year-old male patient who underwent left mandibulectomy flap (LICF). Methods Pacient diagnosed squamous cell carcinoma bucal mucosa. He received adjuvant chemotherapy, had mandibular recurrence, so was decided, collaboration surgeon, LICF...
2544 Background: Several phase I/II trials have shown that the triplet combination of oxaliplatin, irinotecan and capecitabine is a feasible active in solid tumors. We aimed to investigate whether germline polymorphisms may be predictors clinical outcome mCRC pts treated with this combination. Methods: The following genetic were analysed: glutathione S-transferase (GSTP1-Ile105Val, GSTT1 GSTM1 deletion), TYMS (TS-5´UTR 2R/3R; TS-5´G/C; TS-3´UTR 6-bp MTHFR 1298A>C, UGT1A1, ERCC1, XPD....
e20004 Background: Patients with thyroid transcription factor 1 (TTF1) negative lung adenocarcinoma (ADC) have been reported to a worse prognosis and lack epidermal growth receptor (EGFR) mutations. This study describes series of sample tumors from patients clinically confirmed cancer. Methods: In all cancer diagnosed in the University Hospital Lleida January 2011 December 2016, real world data TTF1-negative ADC was performed, using TTF1 clone 8G7G3/1(DAKO). Each patient’s clinical history,...
e12086 Background: Although ECD expression was validated as tumor marker years ago, it is not used in daily clinical practice even if a prognostic value demonstrated some trials. Methods: In our single institution, during January 2013-2019, analyzed series of HER2 positive breast cancer patients; 71 early or locally-advanced and 45 metastatic setting. Results: the cohort, median 28 ng/ml (6,5-350), thus 10 (22%) patients had lower levels than threshold 15ng/ml. No correlation found between...
The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy limited to the progression this treatment.We analyzed efficacy with bevacizumab plus paclitaxel in 43 patients hormone receptor-positive HER2-negative cancer.Paclitaxel combination a useful an impressive overall survival 31 months, similar targeted first line. In resistance, saw worse results thus taxol could be better option. This does not influence subsequent treatments; therefore, it provide...
<h3>Background</h3> We conducted a study using ultrasonography (US) to evidence inflammatory changes (joint-enthesis-ungueal) in active PsA (aPsA) patients who started Apremilast (A) clinical practice. <h3>Objectives</h3> Obtain 20, 50, 70 % reduction the US index (UIC) at 12 months, and correlation between variables. <h3>Methods</h3> <i>Phase IV, multicenter, prospective open-label trial</i> <i>in 9 centres</i> from 2018 2021. All signed informed consent. Approval by ethical committee was...
e13523 Background: Cetuximab has shown a clinically significant antitumor activity against metastatic colorectal cancer (mCRC) both in first and subsequent lines of therapy. Biweekly schedules have similar PK/PD behaviour inhibition EGFR downstream pathway compared to the weekly schedule. Several molecular factors been found predict response Cetuximab. Among them role ADCC suggested. We aimed investigate association Fc gamma Receptor (Fcg R) polymorphisms KRAS mutation with outcome mCRC...